Inovio publishes early positive results for dBiTEs cancer/leukemia approach

342

BiTE ( bispecific T-cell engager ) therapy is a relatively new approach in immunotherapy for cancer. BiTEs are used to help direct tumor killing cells to cancerous tumors, and the effect ranges from slowing cancer tumor growth, to completely halting it. One problem with the current BiTE approach is the cost of generating the BiTE cells.

Inovio thinks they may have a solution to this, which would allow BiTE therapy to become more commonplace, as well as reduce it’s cost, which is currently a barrier to it’s use. This is particularly relevant for those with Leukemia, as BiTE therapy has shown excellent results in treating the disease.

Inovio’s dBiTEs are a large improvement over current BiTE therapy, as BiTE therapy has a half-life of 2.1 hours. dBiTEs have a half life in the timespan of months, providing a long term boost of anti-tumor activity from a single injection.

In the study, published in the Journal of Clinical Investigation, researchers showed that DBiTEs were effective at significantly delaying tumor development in an ovarian cancer model, as well as an aggressive breast cancer model in mice.

This may turn out be an excellent weapon against cancer. Unfortunately, the therapy is still in the very early stages of development as f writing.

For more information, see Inovio’s press release here: http://ir.inovio.com/news-and-media/news/press-release-details/2019/Inovio-Publishes-Cancer-Killing-Data-of-Its-Transformative-DNA-encoded-Bi-specific-T-Cell-Engagers-dBiTEs-in-a-Peer-reviewed-Journal/default.asp